KBC Group NV Invests $857,000 in Phathom Pharmaceuticals, Inc. $PHAT

KBC Group NV bought a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 77,139 shares of the company’s stock, valued at approximately $857,000.

Other large investors also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in Phathom Pharmaceuticals by 508.2% in the 1st quarter. AQR Capital Management LLC now owns 107,399 shares of the company’s stock valued at $673,000 after purchasing an additional 89,741 shares during the period. JPMorgan Chase & Co. grew its holdings in Phathom Pharmaceuticals by 0.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock valued at $1,328,000 after buying an additional 1,123 shares in the last quarter. Rhumbline Advisers increased its position in Phathom Pharmaceuticals by 13.8% during the 2nd quarter. Rhumbline Advisers now owns 64,557 shares of the company’s stock worth $619,000 after buying an additional 7,818 shares during the period. Invesco Ltd. increased its position in Phathom Pharmaceuticals by 13.4% during the 2nd quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock worth $39,703,000 after buying an additional 489,260 shares during the period. Finally, Nebula Research & Development LLC lifted its holdings in shares of Phathom Pharmaceuticals by 31.6% during the second quarter. Nebula Research & Development LLC now owns 37,937 shares of the company’s stock worth $364,000 after buying an additional 9,116 shares in the last quarter. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Stock Performance

PHAT opened at $11.44 on Friday. Phathom Pharmaceuticals, Inc. has a 52-week low of $8.02 and a 52-week high of $18.31. The firm has a market cap of $912.45 million, a P/E ratio of -5.40 and a beta of 0.49. The business’s fifty day moving average is $10.86 and its 200-day moving average is $11.90.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Wednesday, June 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Phathom Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.